Condensed Consolidated Balance Sheets - USD ($) $ in Thousands		Mar. 31, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents		$ 18,011	$ 23,587
Marketable equity securities		9,085	7,154
Trade accounts and grants receivable, net		1,402	767
Receivables from affiliates, net (Note 10)			2,112
Landlord receivable			840
Prepaid expenses and other current assets		2,158	1,898
Total current assets		30,656	36,358
NONCURRENT ASSETS
Property and equipment, net		8,918	5,835
Deposits and other long-term assets		890	505
Promissory note from Juvenescence (Note 5)		22,482	22,104
Goodwill	[1]	12,977
Intangible assets, net		49,829	3,125
TOTAL ASSETS		183,715	101,660
CURRENT LIABILITIES
Accounts payable and accrued liabilities		7,336	6,463
Financing lease and right of use lease liabilities, current portion		954	237
Promissory notes, current portion		18	70
Deferred grant revenue		43	42
Liability classified warrants, current portion		372
Total current liabilities		8,723	6,812
LONG-TERM LIABILITIES
Deferred tax liability		8,581
Deferred revenues, net of current portion		200
Deferred rent liabilities, net of current portion			244
Right-of-use lease liability, net of current portion		4,016	1,854
Financing lease, net of current portion		103	104
Liability classified warrants, net of current portion, and other long-term liabilities		856	400
TOTAL LIABILITIES		22,479	9,414
Commitments and contingencies (Note 15)
SHAREHOLDERS' EQUITY
Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of March 31, 2019 and December 31, 2018
Common shares, no par value, 250,000 shares authorized; 149,388 shares issued and outstanding as of March 31, 2019 and 127,136 shares issued and outstanding as of December 31, 2018		384,553	354,270
Accumulated other comprehensive income		694	1,426
Accumulated deficit		(222,403)	(261,856)
BioTime, Inc. shareholders' equity		162,844	93,840
Noncontrolling interest (deficit)		(1,608)	(1,594)
Total shareholders' equity		161,236	92,246
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		183,715	101,660
OncoCyte Corporation [Member]
NONCURRENT ASSETS
Equity method investment		57,963	20,250
SHAREHOLDERS' EQUITY
Common shares, no par value, 250,000 shares authorized; 149,388 shares issued and outstanding as of March 31, 2019 and 127,136 shares issued and outstanding as of December 31, 2018		58,000
Asterias Biotherapeutics [Member]
NONCURRENT ASSETS
Equity method investment			$ 13,483

[1] Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger (see Note 3).